前循环大血管闭塞患者随机接受静脉阿替普酶联合血管内治疗与单纯血管内治疗的梗死演变
基于MR CLEAN-NO IV试验中145例有基线CTP和随访影像的患者,比较静脉阿替普酶联合血管内治疗与单纯血管内治疗的梗死演变,发现两组间无统计学显著差异,侧支循环状态和闭塞部位可能与梗死进展相关。
要点
- 静脉阿替普酶联合血管内治疗与单纯血管内治疗相比,随访梗死体积与CTP核心体积的演变无统计学显著差异。
- 侧支循环状态和闭塞部位与梗死进展呈负相关,可能有助于预测梗死演变预后。
- 梗死演变定义为随访病灶体积与CTP核心体积之比,显著梗死增长定义为随访梗死体积增加>10 mL。
核心结论
- 在症状发作4.5小时内直接入院并接受静脉阿替普酶联合血管内治疗的患者与单纯血管内治疗患者相比,梗死演变无统计学显著差异;侧支循环状态和闭塞部位可能是接受血管内治疗的静脉阿替普酶 eligible 患者梗死演变预后的有用预测因素。
研究设计与样本
- 来自荷兰急性缺血性卒中血管内治疗多中心随机临床试验(MR CLEAN)-NO IV试验,纳入有基线CTP和随访影像的患者228例中145例有随访影像并纳入分析;随访梗死体积在24小时或1周随访DWI或NCCT上分割;梗死演变定义为随访病灶体积与CTP核心体积之比;显著梗死增长定义为随访梗死体积增加>10 mL;采用多变量回归评估基线特征和手术结局与梗死演变的关系。
诊断标准与关键数值
- 梗死演变定义为随访病灶体积与CTP核心体积之比。
- 显著梗死增长定义为随访梗死体积增加>10 mL。
- 静脉阿替普酶联合血管内治疗组基线中位CTP核心体积为17 mL(四分位距4-35 mL),单纯血管内治疗组为11 mL(四分位距6-24 mL)。
- 静脉阿替普酶联合血管内治疗组中位随访梗死体积为13 mL(四分位距4-48 mL),单纯血管内治疗组为17 mL(四分位距4-50 mL)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Infarct evolution after endovascular treatment varies widely among patients with stroke and may be affected by baseline characteristics and procedural outcomes. Moreover, IV alteplase and endovascular treatment may influence the relationship of these factors to infarct evolution. We aimed to assess whether the infarct evolution between baseline and follow-up imaging was different for patients who received IVT and EVT versus EVT alone.
MATERIALS AND METHODS: We included patients from the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN)-NO IV trial with baseline CTP and follow-up imaging. Follow-up infarct volume was segmented on 24-hour or 1-week follow-up DWI or NCCT. Infarct evolution was defined as the follow-up lesion volume: CTP core volume. Substantial infarct growth was defined as an increase in follow-up infarct volume of >10 mL. We assessed whether infarct evolution was different for patients with IV alteplase and endovascular treatment versus endovascular treatment alone and evaluated the association of baseline characteristics and procedural outcomes with infarct evolution using multivariable regression.
RESULTS: From 228 patients with CTP results available, 145 patients had follow-up imaging and were included in our analysis. For patients with IV alteplase and endovascular treatment versus endovascular treatment alone, the baseline median CTP core volume was 17 (interquartile range = 4-35) mL versus 11 (interquartile range = 6-24) mL. The median follow-up infarct volume was 13 (interquartile range, 4-48) mL versus 17 (interquartile range = 4-50) mL. Collateral status and occlusion location were negatively associated with substantial infarct growth in patients with and without IV alteplase before endovascular treatment.
CONCLUSIONS: No statistically significant difference in infarct evolution was found in directly admitted patients who received IV alteplase and endovascular treatment within 4.5 hours of symptom onset versus patients who underwent endovascular treatment alone. Collateral status and occlusion location may be useful predictors of infarct evolution prognosis in patients eligible for IV alteplase who underwent endovascular treatment.
引用
- Hoving JW, van Voorst H, Kappelhof M, et al. Infarct Evolution in Patients with Anterior Circulation Large-Vessel Occlusion Randomized to IV Alteplase and Endovascular Treatment versus Endovascular Treatment Alone. AJNR Am J Neuroradiol. 2023. PMID: 36958803. doi:10.3174/ajnr.A7826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。